The BioInnovation Institute (BII) in Copenhagen, Denmark, has recently welcomed twelve new companies into its Venture Lab acceleration program, which supports startups poised to make significant contributions to human and planetary health. Among these new entrants, Prenaital and OvartiX are notable for their focus on advancing women’s health.
Prenaital is transforming prenatal care by utilizing AI to improve ultrasound diagnostics, making high-quality prenatal care more accessible. Their AI models enhance the detection of at-risk pregnancies, addressing biases related to BMI, age, race, and parity. This innovation has the potential to prevent thousands of stillbirths and preterm births annually by providing timely and accurate diagnostics, even in underserved communities.
OvartiX is focused on developing next-generation therapeutics for female reproductive health. Using a drug discovery platform that leverages large-scale multi-omics data, human cellular engineering, and in vivo models, OvartiX aims to create advanced treatments for fertility and ovarian function. Their work promises to offer new therapeutic options for women facing reproductive challenges.
These companies will receive support from BII over the next 12 months, including a founder-friendly convertible loan of EUR 500,000, access to labs and offices, and further funding opportunities.
